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Background 
How to manage patients effectively, efficiently and within resource and budget 
constraints? 
Major depression is the leading cause of ill health and disability worldwide.  2017 
marked the year when the World Health Organization led a 1-year global campaign 
with the goal that more people with depression both seek and get help.1,2 
In England, Hospital Episode Statistics and Mental Health and Learning Disabilities 
data sets show that one in three patients with depression are unrecognised.  Those who 
are recognised are often then under-treated, fail to achieve remission and have 
difficulty returning to full functioning.  Both recognised and unrecognised patients 
with major depressive disorder (MDD) often present in acute care, incurring 
substantial costs outside secondary mental health (MH) care.  Guidelines suggest that 
most patients with depression disorders should be managed in primary care, rather 
than by secondary care MH services.3 
The current focus on service provision for people with MH conditions is concentrated 
on meeting Improving Access to Psychological Therapies (IAPT) targets, dementia 
and Early Intervention in Psychosis, Child and Adolescent Mental Health Services, 
rather than optimising the recognition and management of MDD and identifying 
factors that predispose to continued illness. 
Review and appropriate follow-up of patients with MDD is essential if issues 
impairing recovery are to be identified and addressed.  Within IAPT services, 
recovery is measured in terms of “caseness”: a referral is moved to recovery if the 
patient was a clinical case at start of treatment (“at caseness”) and not a clinical case 
3 
 
at end of treatment.4  IAPT services also use a unique session-by-session outcome-
monitoring system to guide clinicians’ choice of procedures and assess the overall 
outcome of a course of therapy.5 
Within primary care, the Quality and Outcomes Framework (QOF) rewards practices 
for provision of “quality care”.6  Under QOF, primary care is only reimbursed for one 
review of a patient with depression (10–35 days after diagnosis) even though regular 
review (every 2–4 weeks in the first 3 months and then at longer intervals) is 
recommended.6  QOF also encourages clinicians to use self-administered 
questionnaires, such as the Patient Health Questionnaire (PHQ-9),7 to identify 
depression and assess treatment response.  In the draft revised NICE depression 
guidelines, clinicians are encouraged to monitor mood state at regular intervals for 
patients who continue on medication to prevent relapse, using a formal validated 
rating scale, eg PHQ-9.8  However, the value of PHQ-9 to guide prescribing or 
measure recovery/response to treatment is called into question because patients may 
not interpret questions in a way that is meaningful to them.9 
Additionally, within QOF there are no requirements to: 
• Differentiate between response and remission: even 50% response or a global 
assessment is not usually used. 
• Determine what “recovery” means: depressive symptoms and/or function? 
• Check for residual symptoms: 
o remaining symptoms of initial depression 
o side effects of antidepressant medication 
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o impact of other co-morbidities/drugs. 
• Decide if a patient qualifies for long-term treatment (recurrent depression). 
Specific challenges for primary care physicians 
The presence of long-term physical illnesses and co-morbid MH disorders may not 
only mask underlying MDD but also negatively impact on recovery.  Even if 
depression is identified, patients are often reluctant to accept the diagnosis and 
treatment because of associated stigma.  Unrecognised and under-treated MDD results 
in suffering for the person, their families and friends, poor functioning, often frequent 
presentations to primary care with apparently minor ailments and inappropriate 
presentations to acute hospital settings. 
Intervention choice depends on several factors: patient choice/acceptability, type and 
severity of depression, need for rapid treatment effect, prior response to treatment and 
prevention of relapse.  Current practice pays little consideration to residual symptoms 
and restoration of functioning when choosing an antidepressant.  Evidence from the 
STAR*D (Sequenced Treatment Alternatives to Relieve Depression) study highlights 
that as more treatment steps are required, lower acute remission rates and higher 
relapse rates occur during the follow-up phase.10,11 
Which pharmacological treatment, when, in which order or which combination for 
which patient? 
Primary care physicians (PCPs) often treat to a ‘NICE Pathway’ rather than 
determining how and where individuals fit into that pathway.  For example, patients 
may be prescribed a selective serotonin reuptake inhibitor (SSRI), even though they 
have not tolerated or responded to SSRIs previously!  A study by Kendrick et al 
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explored the feasibility of using patient-reported outcome measures (PROMs) for 
monitoring primary care patients with depression.12  These included Beck Depression 
Inventory II, Work and Social Adjustment Scale, EuroQol Five-Dimension, Five-
Level scale for quality of life and modified Client Service Receipt Inventory for costs.  
Although patients liked completing PROMs, and this may improve depression 
outcome, practitioners did not use the results to inform management. 
The needs 
Even for patients who achieve remission, those with residual symptoms have poorer 
function and increased risk of relapse.13  A new approach to decision-making for 
choosing MDD treatment in primary care is needed.  As well as amelioration of 
depressive symptoms, the aims should be identification of residual symptoms and 
restoration of normal functioning, so decreasing risk of relapse.14–17 
A prospective clinical study of primary care patients with MDD, followed for 3 years 
during subsequent major episodes and episodes of (partial) remission, demonstrated 
that residual symptoms were common.18  The most frequently occurring were 
cognitive impairment, lack of energy and sleep problems, which were present 39–44% 
of the time during remission.  A second study19 identified cognitive impairment in 
~28% of people with unipolar depression. 
Some aspects of cognitive impairment may improve with treatment but many patients 
experience significant problems with attention, executive functioning, immediate 
recall and processing speed, despite achieving remission.20  Continued impairment is a 
risk factor for future depression14 and associated with poorer response to treatment. 
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Differential diagnosis of residual cognitive impairment includes co-morbid physical 
or psychiatric diagnoses, discontinuation syndrome associated with non-compliance, 
incorrect diagnosis, psychosocial factors, medication side effects and, in older 
patients, dementia.  Because primary care plays a major role in screening for cognitive 
impairment in people at risk of dementia, clinicians are familiar with identifying these 
aspects of cognitive impairment but less familiar with the frequent longer-term side 
effects of commonly prescribed antidepressants (SSRIs and serotonin–noradrenaline 
reuptake inhibitors): apathy, decreased motivation, fatigue and cognitive dulling. 
Residual symptoms should be identified after depressive symptoms have responded to 
treatment (4–8 weeks) or remitted (6–12 weeks) and other causes have been excluded.  
A challenge for most PCPs is that they may not understand the various domains of 
cognitive impairment, such as executive function, working memory, episodic 
memory, attention and psychomotor processing speed.20,21 
So what tools are suitable and available to assist PCPs in identifying residual 
symptoms?  The Conradi study used the Composite International Diagnostic 
Interview (CIDI).  Most GPs will not have used the CIDI but will instead be more 
familiar with tools used to screen for cognitive impairment associated with dementia, 
not suitable for patients with depression. 
In a recent survey, UK PCPs and psychiatrists recognised cognitive dysfunction as an 
area of unmet need and that there is a lack of objective tests of cognition appropriate 
for patients with depression that can be easily implemented in primary or secondary 
care.22  Currently, there is no consensus about the best tools or test battery to 
accurately and efficiently assess cognitive impairment associated with depression in 
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clinical practice.  Nor are there data to refute or confirm that the same tools can be 
used in younger and older adults, male and female. 
Equally, there is a paucity of data about how best to manage residual cognitive 
impairment.  Do individual antidepressants differ in their ability to minimise cognitive 
impairment?  Are combinations of drugs, combination drug and psychological 
therapies or augmentation strategies more effective?  Which psychological 
interventions are appropriate?  Should the treatment approach be tailored to the type 
of cognitive impairment or certain patient characteristics?  Concerns have been raised 
in the past about the increased use of antidepressants, with insinuations that this was 
inappropriate.23  An analysis of the national GP research database showed that the 
increased use was not due to more people receiving antidepressants but rather to more 
appropriate prescribing in line with national guidelines (6-month minimum 
recommended treatment rather than 1 month as per previous common practice).24 
Professionals, patients and politicians need to be reminded that although MDD is 
labelled as a common MH problem, it has serious health, social and economic 
consequences.  Outcomes after pharmacological treatment should not only target 
depressive symptoms but also acknowledge the detrimental effect residual symptoms 
can have on likelihood of full recovery and, like IAPT, focus on restoring function.  
Consensus is needed regarding identifying residual symptoms, and more research is 
required about the value of currently available treatments and to identify improved 
therapeutic strategies. 
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Conclusion 
Depression is the leading cause of disability in the world, achieving this status 
nearly two decades earlier than predicted.  A different management approach is 
required, with restoration of normal functioning, rather than just remission of 
depressive symptoms, the goal of treatment.  Clinicians, especially those in primary 
care, need to understand the relationship between residual symptoms and risk of 
relapse and impaired functioning.  Pathways of care should include identification of 
residual symptoms, especially cognitive impairment, for all patients treated for 
depression, including those who have remitted.  More research is needed to 
determine the best tools to detect residual symptoms, how best to manage such 
symptoms and whether the approach should be the same in all patient populations. 
Dr Rasmussen is an Independent Consultant and Primary Care Specialist Mental 
Health in Dementia and Learning Disability working in Dorking and Dr Young is a 
Director in the Centre for Affective Disorders at the Institute of Psychiatry, 
Psychology & Neuroscience (IoPPN) at King’s College London. 
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